Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen

NCT03013335 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

730

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Renal Cell Carcinoma

Interventions

DRUG: Nivolumab

Sponsor

UNICANCER

Collaborators

[object Object]